08048035968
Premium Exporter of Genuine KEYTRUDA 100mg Injection from India to Singapore – Orchard |Phoenix Exim

1. General Information

KEYTRUDA is the brand name for pembrolizumab, a PD-1 immune checkpoint inhibitor. It is used in several cancer treatment settings, either alone or together with other anticancer medicines, depending on the patient's cancer type, stage, biomarker status, and treatment history.

It is a prescription-only oncology medicine and should be used only under the supervision of a qualified oncologist.

2. Product Information

  • Brand Name: KEYTRUDA
  • Active Ingredient: Pembrolizumab
  • Strength: 100 mg/4 mL (25 mg/mL)
  • Dosage Form: Injection
  • Route: Intravenous (IV) infusion
  • Drug Class: PD-1 blocking monoclonal antibody / immunotherapy
  • Manufacturer: Merck Sharp & Dohme LLC
  • Presentation: Single-dose vial
  • Storage: Store and handle according to the manufacturer's approved product labeling and cold-chain requirements.

3. Uses of KEYTRUDA 100 mg Injection

KEYTRUDA is approved for a range of cancers and treatment settings. Depending on the specific indication and applicable regulatory approval, it may be used for cancers including:

  • Melanoma
  • Non-small cell lung cancer (NSCLC)
  • Head and neck squamous cell carcinoma
  • Classical Hodgkin lymphoma
  • Urothelial carcinoma
  • Renal cell carcinoma
  • Certain colorectal cancers
  • Certain gastric or gastroesophageal cancers
  • Certain esophageal cancers
  • Certain breast cancers
  • Certain cervical cancers
  • Other approved solid tumors based on specific disease and biomarker criteria

The exact indication should be confirmed against the current prescribing information for the patient's country and individual clinical situation.

4. Benefits of KEYTRUDA

KEYTRUDA may provide the following therapeutic benefits when appropriately prescribed:

  • Helps activate the body's immune response against cancer cells.
  • Can be used as monotherapy for certain cancers.
  • Can be combined with chemotherapy, targeted medicines, radiotherapy, or other cancer treatments for selected indications.
  • May help control tumor growth and disease progression in eligible patients.
  • Provides an important immunotherapy option for patients whose cancer meets the relevant treatment criteria.

The response to treatment varies between patients and depends on cancer type, stage, biomarkers, previous treatment, and overall health.

5. Side Effects of KEYTRUDA

Because pembrolizumab stimulates the immune system, it can sometimes cause the immune system to attack healthy organs. These immune-mediated reactions can affect the lungs, liver, intestines, kidneys, endocrine glands, skin, nervous system, heart, and other organs and can occasionally be serious or life-threatening.

Seek prompt medical attention for symptoms such as:

  • New or worsening cough or breathing difficulty
  • Severe or persistent diarrhea or abdominal pain
  • Yellowing of the skin or eyes
  • Significant changes in urine output
  • Severe rash or blistering
  • Severe weakness or unusual fatigue
  • Confusion, dizziness, fainting, or neurological symptoms
  • Changes in heartbeat or chest pain
  • Significant changes in vision

6. Common Side Effects

Common adverse effects vary according to whether KEYTRUDA is used alone or with other treatments. When used alone, commonly reported reactions include:

  • Fatigue
  • Musculoskeletal pain
  • Rash
  • Diarrhea
  • Fever
  • Cough
  • Decreased appetite
  • Itching
  • Shortness of breath
  • Constipation
  • Abdominal pain
  • Nausea
  • Low thyroid hormone / hypothyroidism

When KEYTRUDA is combined with chemotherapy or other anticancer medicines, additional effects such as vomiting, hair loss, anemia, neuropathy, mouth inflammation, headache, weight loss, and other treatment-related reactions may occur.

7. How to Use KEYTRUDA 100 mg Injection

KEYTRUDA must be administered by a qualified healthcare professional.

The medicine is given through an intravenous infusion, generally over approximately 30 minutes. The dosing schedule depends on the approved indication, patient's age, treatment regimen, and clinical circumstances. Adult regimens may use administration every 3 weeks or every 6 weeks depending on the prescribed dose and indication.

Patients should not self-administer KEYTRUDA. The oncologist determines the appropriate dose, treatment duration, and whether treatment should be delayed or discontinued.

8. How KEYTRUDA Works

Pembrolizumab is a PD-1 receptor-blocking antibody.

Some cancer cells can use the PD-1 pathway to reduce the activity of immune cells that would otherwise attack them. Pembrolizumab blocks the interaction between PD-1 and its ligands, helping restore T-cell activity against cancer cells.

In simple terms, KEYTRUDA helps remove an immune-system “brake”, allowing the immune system to better recognize and fight certain cancer cells.

9. Safety Advice for KEYTRUDA

  • Use only under the supervision of an oncologist.
  • Inform your doctor about all medicines, supplements, and treatments you are receiving.
  • Tell your healthcare provider about previous immune-related problems or organ conditions.
  • Regular blood tests and clinical monitoring may be required during treatment.
  • Report new or worsening symptoms promptly, even if they appear several weeks or months after treatment.
  • Inform your healthcare provider if you are pregnant, planning pregnancy, or breastfeeding.
  • Pembrolizumab can cause fetal harm; effective contraception may be recommended for patients who can become pregnant.
  • KEYTRUDA may need to be withheld or permanently discontinued if serious immune-mediated adverse reactions occur.
  • Do not change the dose or treatment schedule without medical advice.

10. FAQs

Q1. What is KEYTRUDA 100 mg Injection?
KEYTRUDA 100 mg Injection contains pembrolizumab, a PD-1 immune checkpoint inhibitor used for certain cancers.

Q2. Is KEYTRUDA a chemotherapy medicine?
No. KEYTRUDA is an immunotherapy medicine. It works by helping the immune system recognize and attack cancer cells.

Q3. How is KEYTRUDA administered?
The intravenous formulation is administered by a healthcare professional through an IV infusion.

Q4. How often is KEYTRUDA given?
The schedule depends on the indication and prescribed dose. Some adult treatment regimens are administered every 3 weeks or every 6 weeks.

Q5. Can KEYTRUDA be used for every type of cancer?
No. Its use is limited to specific approved cancer indications and, in some cases, particular biomarker or treatment criteria.

Q6. Does KEYTRUDA have serious side effects?
Yes. Because it activates the immune system, it can cause immune-mediated reactions that may affect different organs and can sometimes be severe.

Q7. Can KEYTRUDA be combined with other cancer medicines?
Yes. Depending on the cancer and approved treatment regimen, KEYTRUDA may be combined with chemotherapy, targeted medicines, or other therapies.

Q8. Who decides whether KEYTRUDA is appropriate?
A qualified oncologist should determine whether pembrolizumab is appropriate based on the cancer diagnosis, clinical condition, test results, previous treatment, and applicable treatment guidelines.

11. Substitute for KEYTRUDA

The appropriate substitute depends on the cancer type, biomarker status, treatment line, previous therapies, and country-specific approvals. There is no single universal substitute for KEYTRUDA.

Other medicines in the broader immunotherapy/PD-1 or PD-L1 inhibitor category may sometimes be considered by an oncologist, such as:

  • Nivolumab
  • Cemiplimab
  • Atezolizumab
  • Durvalumab
  • Dostarlimab

These medicines are not automatically interchangeable with KEYTRUDA. The choice must be made by the treating oncologist according to the specific cancer and approved indication.

12. Keywords

  • KEYTRUDA 100 mg Injection
  • Keytruda 100 mg
  • Pembrolizumab 100 mg Injection
  • Pembrolizumab Injection exporter
  • Pembrolizumab 100 mg supplier
  • KEYTRUDA supplier from India
  • KEYTRUDA exporter from India
  • KEYTRUDA medicine exporter
  • Pembrolizumab oncology medicine
  • Pembrolizumab immunotherapy
  • PD-1 inhibitor medicine
  • Cancer immunotherapy injection
  • Oncology injection supplier
  • Cancer medicine exporter India
  • KEYTRUDA 100 mg vial supplier
  • Pembrolizumab injection supplier India
  • KEYTRUDA pharmaceutical exporter
  • Genuine KEYTRUDA supplier
  • KEYTRUDA 100 mg international supplier
  • Pembrolizumab medicine exporter Nagpur
  • Cancer treatment medicine exporter India
  • Oncology medicines exporter India
  • KEYTRUDA export supplier
  • Pembrolizumab 100 mg international supplier
  • KEYTRUDA supplier USA
  • KEYTRUDA supplier UK
  • KEYTRUDA supplier Australia
  • KEYTRUDA supplier Singapore
  • KEYTRUDA supplier Canada
  • KEYTRUDA supplier South Korea
  • KEYTRUDA supplier UAE


Aug 20th, 2026 2:39 PM

Keywords